Target intelligence / Profile preview

Pulmonary edema

01

Overview

Pulmonary edema is an abnormal accumulation of fluid in the air sacs (alveoli) and lung tissue, leading to impaired gas exchange and difficulty breathing. It is most commonly caused by heart conditions such as congestive heart failure but can also result from non-cardiac causes including pneumonia, sepsis, kidney failure, exposure to toxins or high altitude, trauma, or drug reactions. Symptoms include shortness of breath—especially when lying down—coughing up frothy sputum that may be blood-stained, wheezing, chest pain or tightness, anxiety and restlessness. Acute pulmonary edema is a medical emergency requiring immediate intervention with oxygen therapy and medications to address the underlying cause. Chronic forms may develop more slowly but still require prompt management to prevent life-threatening complications.[1][2][3] **Note:** "Airway edema" is not a molecular target but rather a clinical condition describing swelling due to fluid accumulation within the airway structures. The correct canonical term for this context is "pulmonary edema," which refers specifically to fluid buildup in the lungs' alveoli rather than just any airway swelling. There are no specific receptors or molecules named "airway edema"; thus it should not be considered a therapeutic target like an enzyme or receptor would be.[2]

Other names
Lung congestionLung waterPulmonary congestionHeart failure - pulmonary edema[4][2]
02

Mechanism of action

Diuretics reduce fluid overload by increasing urine output. - Vasodilators decrease cardiac preload and afterload, reducing pulmonary capillary pressure. - Oxygen therapy increases oxygenation when gas exchange is impaired.[1][3]

03

Disease associations

Cardiovascular diseaseInflammationInfectionOther (as a complication of trauma, drug reaction, or high altitude)[1][2][5]
04

Safety considerations

Risk of respiratory failure and hypoxemia if untreatedPotential for permanent organ damage with delayed treatment[2][6]
05

Interacting drugs

Diuretics (e.g., furosemide)

3 more in the full profile.

06

Biomarkers

B-type natriuretic peptide (BNP) for heart failure-related casesTroponin for cardiac injury assessment[2]

Beyond the preview

Go deeper on Pulmonary edema.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pulmonary edema.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call